XR 808

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341463

CAS#: 167826-88-2

Description: XR 808 is a biochemical.


Price and Availability

Size
Price

Size
Price

Size
Price

XR 808 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 341463
Name: XR 808
CAS#: 167826-88-2
Chemical Formula: C17H34N2O3
Exact Mass: 314.2569
Molecular Weight: 314.47
Elemental Analysis: C, 64.93; H, 10.90; N, 8.91; O, 15.26


Synonym: XR-808; XR 808; XR808; .

IUPAC/Chemical Name: (4R-(4alpha,5alpha,6beta,7beta))-Hexahydro-5,6-dihydroxy-4,7-bis(2-ethylbutyl)-2H-1,3-diazepin-2-one

InChi Key: KNEDFLBGINWTSV-WCVJEAGWSA-N

InChi Code: InChI=1S/C17H34N2O3/c1-5-11(6-2)9-13-15(20)16(21)14(19-17(22)18-13)10-12(7-3)8-4/h11-16,20-21H,5-10H2,1-4H3,(H2,18,19,22)/t13-,14-,15+,16+/m1/s1

SMILES Code: O=C1N[C@H](CC(CC)CC)[C@H](O)[C@@H](O)[C@@H](CC(CC)CC)N1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Zhang Y, Lei BH, Zou Q, Zhu QY, Lu ZJ, Wang Y. [Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. Zhonghua Nan Ke Xue. 2017 Oct;23(10):922-927. Chinese. PubMed PMID: 29727544.

2: Chauchat L, Tanguay C, Caron NJ, Gagné S, Labrèche F, Bussières JF. Surface contamination with ten antineoplastic drugs in 83 Canadian centers. J Oncol Pharm Pract. 2018 Jan 1:1078155218773862. doi: 10.1177/1078155218773862. [Epub ahead of print] PubMed PMID: 29726786.

3: Pandey G, Mittapelly N, Banala VT, Mishra PR. Multifunctional Glycoconjugate Assisted Nanocrystalline Drug Delivery for Tumor Targeting and Permeabilization of Lysosomal-Mitochondrial Membrane. ACS Appl Mater Interfaces. 2018 May 4. doi: 10.1021/acsami.7b18699. [Epub ahead of print] PubMed PMID: 29726253.

4: Škereňová M, Mikulová V, Čapoun O, Švec D, Kološtová K, Soukup V, Honová H, Hanuš T, Zima T. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. Mol Diagn Ther. 2018 May 3. doi: 10.1007/s40291-018-0333-0. [Epub ahead of print] PubMed PMID: 29725990.

5: Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P. (68)Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018 May 3. doi: 10.1007/s00259-018-4042-z. [Epub ahead of print] PubMed PMID: 29725716.

6: Hiroshige T, Eguchi Y, Yoshizumi O, Chikui K, Kumagai H, Kawaguchi Y, Onishi R, Hayashi T, Watanabe K, Mitani T, Saito K, Igawa T. Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. Oncol Lett. 2018 May;15(5):6806-6814. doi: 10.3892/ol.2018.8263. Epub 2018 Mar 14. PubMed PMID: 29725416; PubMed Central PMCID: PMC5920147.

7: Tang M, Horsley P, Lewis CR. Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy. Intern Med J. 2018 May;48(5):583-587. doi: 10.1111/imj.13785. PubMed PMID: 29722200.

8: Marin S, Querol R, Campins L, Miarons M, Font A, Lianes P. Long-term abiraterone withdrawal syndrome. J Clin Pharm Ther. 2018 May 2. doi: 10.1111/jcpt.12693. [Epub ahead of print] PubMed PMID: 29722038.

9: Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2018 May 2. doi: 10.1007/s00280-018-3560-5. [Epub ahead of print] PubMed PMID: 29721850.

10: Basade M, Singhal M, Rathi AK, Nandi M, Minhas S, Goswami C, Shinde S, Parikh PM, Aggarwal S. Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer. South Asian J Cancer. 2018 Apr-Jun;7(2):146-150. doi: 10.4103/sajc.sajc_123_18. PubMed PMID: 29721483; PubMed Central PMCID: PMC5909294.

11: Shimanuki M, Imanishi Y, Sato Y, Nakahara N, Totsuka D, Sato E, Iguchi S, Sato Y, Soma K, Araki Y, Shigetomi S, Yoshida S, Uno K, Ogawa Y, Tominaga T, Ikari Y, Nagayama J, Endo A, Miura K, Tomioka T, Ozawa H, Ogawa K. Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. Oncotarget. 2018 Apr 10;9(27):18970-18984. doi: 10.18632/oncotarget.24863. eCollection 2018 Apr 10. PubMed PMID: 29721176; PubMed Central PMCID: PMC5922370.

12: Chen BT, Sethi SK, Jin T, Patel SK, Ye N, Sun CL, Rockne RC, Haacke EM, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A. Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res. 2018 May 2;20(1):38. doi: 10.1186/s13058-018-0965-3. PubMed PMID: 29720224.

13: Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J. Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review. Hered Cancer Clin Pract. 2018 Apr 27;16:9. doi: 10.1186/s13053-018-0092-2. eCollection 2018. PubMed PMID: 29719582; PubMed Central PMCID: PMC5924493.

14: Su CY, Chen M, Chen LC, Ho YS, Ho HO, Lin SY, Chuang KH, Sheu MT. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Drug Deliv. 2018 Nov;25(1):1066-1079. doi: 10.1080/10717544.2018.1466936. PubMed PMID: 29718725.

15: Uemura K, Miyoshi Y, Kawahara T, Ryosuke J, Yamashita D, Yoneyama S, Yokomizo Y, Kobayashi K, Kishida T, Yao M, Uemura H. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. BMC Cancer. 2018 May 2;18(1):501. doi: 10.1186/s12885-018-4401-y. PubMed PMID: 29716525.

16: Lin JZ, Zhu JG, Wu HF, Li JM, DE W, Wang ZJ. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells]. Zhonghua Nan Ke Xue. 2017 Apr;23(4):302-308. Chinese. PubMed PMID: 29714413.

17: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 Apr 30. doi: 10.1038/s41591-018-0009-7. [Epub ahead of print] PubMed PMID: 29713086.

18: Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 Apr 6. pii: S1558-7673(18)30089-2. doi: 10.1016/j.clgc.2018.03.016. [Epub ahead of print] PubMed PMID: 29706503.

19: Iocca O, Farcomeni A, Di Rocco A, Di Maio P, Golusinski P, Pardiñas López S, Savo A, Pellini R, Spriano G. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options. Oral Oncol. 2018 May;80:40-51. doi: 10.1016/j.oraloncology.2018.03.001. Epub 2018 Mar 27. PubMed PMID: 29706187.

20: Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE. Human gastric cancer modelling using organoids. Gut. 2018 Apr 27. pii: gutjnl-2017-314549. doi: 10.1136/gutjnl-2017-314549. [Epub ahead of print] PubMed PMID: 29703791.